Advertisement Icon completes acquisition of remaining stake in Beacon Bioscience - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Icon completes acquisition of remaining stake in Beacon Bioscience

Icon, a provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has completed the acquisition of the remaining 30% shareholding of Beacon Bioscience, a provider of medical imaging solutions.

Icon has previously acquired a 70% stake in Beacon Bioscience. Beacon Bioscience was renamed Icon Medical Imaging in 2007.

Peter Gray, CEO of Icon, said: “Medical imaging is playing an ever-increasing role in the development of new drugs and treatments. Through technology innovation, astute business management and a team of highly-skilled industry experts, Icon Medical Imaging has become a leader in its field. We believe that now is the right time to complete the acquisition of the remaining stake in the business.”